PrimeVigilance Boosts Efficiency and Safety with Oracle Argus Platform Partnership

Reuters
08 Jul
PrimeVigilance Boosts Efficiency and Safety with Oracle Argus Platform Partnership

Oracle Corporation has announced that PrimeVigilance, a Contract Research Organization, is enhancing its pharmacovigilance service offerings using Oracle Argus. This AI-powered platform aims to improve data management, accuracy, and patient safety. As part of the Ergomed Group, PrimeVigilance is utilizing Argus to optimize drug development programs and ensure regulatory compliance. Additionally, PrimeVigilance has joined Oracle's Lighthouse development program, contributing its expertise to further accelerate pharmacovigilance excellence across the life sciences industry. Oracle Argus is recognized as a leading platform, processing 10 million adverse event cases annually, and is now set to enhance safety monitoring and efficiency for PrimeVigilance's operations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oracle Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: SF24013) on July 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10